EDUCATION

Undergraduate Degree

  • Pennsylvania State University , 1979 , University Park , PA

Medical School

  • Jefferson Medical College , 1983 , Philadelphia , PA

Internship

  • Massachusetts General Hospital , 1984 , Boston , MA

Residency

  • Massachusetts General Hospital , 1987 , Boston , MA

Fellowship

  • Boston Children's Hospital , 1989 , Boston , MA

PROFESSIONAL HISTORY

Lynda Schneider received her MD from Jefferson Medical College.  She completed an internship and residency at Massachusetts General Hospital and a postdoctoral fellowship at Boston Children’s Hospital.  Dr. Schneider received the 2004 AAAAI/Aventis Women in Allergy Project Grant Award.  In 2009, she served as a member of the NIH Food Allergy Clinical Guideline Expert Panel.  In 2011, she was the Chair on the Atopic Dermatitis Practice Parameter Workgroup.

Key Publications

  1. MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, Heimall J, Makhija M, Robison R, Chinthrajah RS, Lee J, Lebovidge J, Dominguez T, Rooney C, Lewis MO, Koss J, Burke-Roberts E, Chin K, Logvinenko T, Pongracic JA, Umetsu DT, Spergel J, Nadeau KC, Schneider LC. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017 Mar; 139(3):873-881.e8.

  2. LeBovidge JS, Elverson W, Timmons KG, Hawryluk EB, Rea C, Lee M, Schneider LC. Multidisciplinary interventions in the management of atopic dermatitis. J Allergy Clin Immunol. 2016 Aug; 138(2):325-34.

  3. Schneider L, Hanifin J, Boguniewicz M, Eichenfield LF, Spergel JM, Dakovic R, Paller AS. Study of the Atopic March: Development of Atopic Comorbidities. Pediatr Dermatol. 2016 Jul; 33(4):388-98.

  4. LeBovidge JS, Michaud A, Deleon A, Harada L, Waserman S, Schneider L. Evaluating a handbook for parents of children with food allergy: a randomized clinical trial. Ann Allergy Asthma Immunol. 2016 Mar; 116(3):230-236.e1.

CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics
  • American Board of Allergy and Immunology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors. J Allergy Clin Immunol. 2021 Jun 07. View abstract
  2. Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum. Allergy. 2021 Aug; 76(8):2510-2523. View abstract
  3. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Am J Clin Dermatol. 2021 Mar; 22(2):243-255. View abstract
  4. Improving patient education for atopic dermatitis: A randomized controlled trial of a caregiver handbook. Pediatr Dermatol. 2021 Mar; 38(2):396-404. View abstract
  5. Severity grading system for acute allergic reactions: A multidisciplinary Delphi study. J Allergy Clin Immunol. 2021 Jul; 148(1):173-181. View abstract
  6. Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study. J Allergy Clin Immunol. 2020 11; 146(5):1089-1096. View abstract
  7. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. J Allergy Clin Immunol. 2020 10; 146(4):863-874. View abstract
  8. Nickel Allergic Contact Dermatitis: Identification, Treatment, and Prevention. Pediatrics. 2020 05; 145(5). View abstract
  9. Combining teledermatology with nonphysician members of the health care team to address access and compliance barriers in pediatric atopic dermatitis: A needs assessment. J Am Acad Dermatol. 2020 Jul; 83(1):237-239. View abstract
  10. Replicated methylation changes associated with eczema herpeticum and allergic response. Clin Epigenetics. 2019 08 23; 11(1):122. View abstract
  11. Reply. J Allergy Clin Immunol Pract. 2019 04; 7(4):1376-1377. View abstract
  12. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019 03 12; 321(10):946-955. View abstract
  13. Identification of children with anaphylaxis at low risk of receiving acute inpatient therapies. PLoS One. 2019; 14(2):e0211949. View abstract
  14. Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodies. Ann Allergy Asthma Immunol. 2019 02; 122(2):213-215. View abstract
  15. Acquired Cold-Induced Urticaria in Pediatric Patients: A 22-Year Experience in a Tertiary Care Center (1996-2017). J Allergy Clin Immunol Pract. 2019 03; 7(3):1024-1031.e3. View abstract
  16. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab. J Allergy Clin Immunol Pract. 2019 02; 7(2):451-461.e7. View abstract
  17. A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018. Ann Allergy Asthma Immunol. 2018 12; 121(6):722-728.e1. View abstract
  18. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy. 2018 07; 48(7):825-836. View abstract
  19. Developing drugs for treatment of atopic dermatitis in children (=3 months to <18 years of age): Draft guidance for industry. Pediatr Dermatol. 2018 May; 35(3):303-322. View abstract
  20. Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing. PLoS One. 2018; 13(2):e0191987. View abstract
  21. Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment. J Allergy Clin Immunol Pract. 2018 Sep - Oct; 6(5):1711-1716.e4. View abstract
  22. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA. 2017 11 14; 318(18):1798-1809. View abstract
  23. Combining anti-IgE with oral immunotherapy. Pediatr Allergy Immunol. 2017 Nov; 28(7):619-627. View abstract
  24. Reducing Hospitalization Rates for Children With Anaphylaxis. Pediatrics. 2017 Jun; 139(6). View abstract
  25. Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Summary of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. J Acad Nutr Diet. 2017 05; 117(5):788-793. View abstract
  26. Ditching the Itch with Anti-Type 2 Cytokine Therapies for Atopic Dermatitis. N Engl J Med. 2017 03 02; 376(9):878-879. View abstract
  27. Addendum guidelines for the prevention of peanut allergy in the United States. JAAPA. 2017 Mar; 30(3):1-5. View abstract
  28. A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis. J Allergy Clin Immunol. 2017 May; 139(5):1575-1582.e8. View abstract
  29. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Ann Allergy Asthma Immunol. 2017 02; 118(2):166-173.e7. View abstract
  30. Addendum guidelines for the prevention of peanut allergy in the United States: Summary of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Pediatr Dermatol. 2017 Jan; 34(1):5-12. View abstract
  31. Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. Pediatr Dermatol. 2017 Jan; 34(1):e1-e21. View abstract
  32. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. J Allergy Clin Immunol. 2017 Jan; 139(1):29-44. View abstract
  33. Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. J Pediatr Nurs. 2017 Jan - Feb; 32:91-98. View abstract
  34. Temporal and Racial Differences Associated with Atopic Dermatitis Staphylococcusaureus and Encoded Virulence Factors. mSphere. 2016 Nov-Dec; 1(6). View abstract
  35. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017 Mar; 139(3):873-881.e8. View abstract
  36. Multidisciplinary interventions in the management of atopic dermatitis. J Allergy Clin Immunol. 2016 08; 138(2):325-34. View abstract
  37. Implementation of a Standardized Clinical Assessment and Management Plan (SCAMP) for Food Challenges. J Allergy Clin Immunol Pract. 2017 Mar - Apr; 5(2):335-344.e3. View abstract
  38. Study of the Atopic March: Development of Atopic Comorbidities. Pediatr Dermatol. 2016 Jul; 33(4):388-98. View abstract
  39. Chronic mucocutaneous candidiasis associated with an SH2 domain gain-of-function mutation that enhances STAT1 phosphorylation. J Allergy Clin Immunol. 2016 07; 138(1):297-299. View abstract
  40. Evaluating a handbook for parents of children with food allergy: a randomized clinical trial. Ann Allergy Asthma Immunol. 2016 Mar; 116(3):230-236.e1. View abstract
  41. Food Allergy in Infants With Atopic Dermatitis: Limitations of Food-Specific IgE Measurements. Pediatrics. 2015 Dec; 136(6):e1530-8. View abstract
  42. Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum. J Allergy Clin Immunol. 2015 Dec; 136(6):1591-1600. View abstract
  43. Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review. Pediatr Allergy Immunol. 2015 Sep; 26(6):537-44. View abstract
  44. Oral immunotherapy and anti-IgE antibody treatment for food allergy. World Allergy Organ J. 2015; 8(1):20. View abstract
  45. A Review of Multidisciplinary Interventions in Atopic Dermatitis. J Clin Med. 2015 May 21; 4(5):1156-70. View abstract
  46. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome associated with neonatal epidermolysis bullosa acquisita. Pediatr Dermatol. 2015 May-Jun; 32(3):e74-7. View abstract
  47. Ovomucoid specific immunoglobulin E as a predictor of tolerance to cooked egg. Allergy Rhinol (Providence). 2015 Jan; 6(3):198-204. View abstract
  48. Oral immunotherapy induces IgG antibodies that act through Fc?RIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014 Dec; 134(6):1310-1317.e6. View abstract
  49. Clinical management of atopic dermatitis: practical highlights and updates from the atopic dermatitis practice parameter 2012. J Allergy Clin Immunol Pract. 2014 Jul-Aug; 2(4):361-9; quiz 370. View abstract
  50. Flow cytometry biomarkers distinguish DOCK8 deficiency from severe atopic dermatitis. Clin Immunol. 2014 Feb; 150(2):220-4. View abstract
  51. Eczema and sensitization to common allergens in the United States: a multiethnic, population-based study. Pediatr Dermatol. 2014 Jan-Feb; 31(1):21-6. View abstract
  52. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013 Dec; 132(6):1368-74. View abstract
  53. Atopic dermatitis complicated by eczema herpeticum is associated with HLA B7 and reduced interferon-?-producing CD8+ T cells. Br J Dermatol. 2013 Sep; 169(3):700-3. View abstract
  54. Prenatal food allergen exposures and odds of childhood peanut, tree nut, or sesame seed sensitization. Ann Allergy Asthma Immunol. 2013 Nov; 111(5):391-6. View abstract
  55. Ovomucoid is not superior to egg white testing in predicting tolerance to baked egg. J Allergy Clin Immunol Pract. 2013 Jul-Aug; 1(4):354-60. View abstract
  56. A holistic view on dermatitis: patch testing should be considered in patients with atopic dermatitis. Reply. J Allergy Clin Immunol. 2013 Sep; 132(3):772. View abstract
  57. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013 Feb; 131(2):295-9.e1-27. View abstract
  58. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013 Mar; 1(2):142-51. View abstract
  59. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. Pediatr Allergy Immunol. 2013 Feb; 24(1):54-60. View abstract
  60. Predicting food challenge outcomes for baked milk: role of specific IgE and skin prick testing. Ann Allergy Asthma Immunol. 2012 Nov; 109(5):309-313.e1. View abstract
  61. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol. 2012 May 13; 13(6):612-20. View abstract
  62. Role of specific IgE and skin-prick testing in predicting food challenge results to baked egg. Allergy Asthma Proc. 2012 May-Jun; 33(3):275-81. View abstract
  63. Effect of cat and daycare exposures on the risk of asthma in children with atopic dermatitis. Allergy Asthma Proc. 2012 May-Jun; 33(3):282-8. View abstract
  64. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol. 2012 May; 5(3):267-76. View abstract
  65. Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum. J Invest Dermatol. 2012 Mar; 132(3 Pt 1):650-7. View abstract
  66. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study. Allergy. 2011 Dec; 66(12):1604-11. View abstract
  67. Predictors of clinical success in a multidisciplinary model of atopic dermatitis treatment. Allergy Asthma Proc. 2011 Sep-Oct; 32(5):377-83. View abstract
  68. Severe atopic dermatitis and transient hypogammaglobulinemia in children. Pediatr Dermatol. 2012 Jan-Feb; 29(1):73-8. View abstract
  69. The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections. J Allergy Clin Immunol. 2011 Nov; 128(5):1006-14. View abstract
  70. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol. 2011 Jun; 127(6):1622-4. View abstract
  71. Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis. J Allergy Clin Immunol. 2011 Jul; 128(1):242-246.e5. View abstract
  72. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-? response. J Allergy Clin Immunol. 2011 Apr; 127(4):965-73.e1-5. View abstract
  73. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored Expert Panel Report. Nutrition. 2011 Feb; 27(2):253-67. View abstract
  74. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored Expert Panel report. J Am Acad Dermatol. 2011 Jan; 64(1):175-92. View abstract
  75. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. Nutr Res. 2011 Jan; 31(1):61-75. View abstract
  76. Research abstracts presented at the Fall Meeting of the New England Society of Allergy, October 23-24, 2010, Woodstock, Vermont. Allergy Asthma Proc. 2011 Jan 01; 32(1):80-81. View abstract
  77. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011 Mar; 127(3):773-86.e1-7. View abstract
  78. Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls. J Allergy Clin Immunol. 2010 Dec; 126(6):1306-7.e2. View abstract
  79. Characterizing the relationship between sesame, coconut, and nut allergy in children. Pediatr Allergy Immunol. 2010 Dec; 21(8):1114-8. View abstract
  80. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010 Dec; 126(6 Suppl):S1-58. View abstract
  81. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol. 2010 12; 126(6):1105-18. View abstract
  82. Tree nut allergy, egg allergy, and asthma in children. Clin Pediatr (Phila). 2011 Feb; 50(2):133-9. View abstract
  83. Hypersensitivity to systemic corticosteroids: an infrequent but potentially life-threatening condition. J Allergy Clin Immunol. 2011 Feb; 127(2):524-8. View abstract
  84. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol. 2010 Nov; 30(6):823-9. View abstract
  85. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. J Allergy Clin Immunol. 2010 Jun; 125(6):1403-1407.e4. View abstract
  86. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics. 2010 May; 125(5):e1024-30. View abstract
  87. Assessment of psychological distress among children and adolescents with food allergy. J Allergy Clin Immunol. 2009 Dec; 124(6):1282-8. View abstract
  88. Sesame allergy: role of specific IgE and skin-prick testing in predicting food challenge results. Allergy Asthma Proc. 2009 Nov-Dec; 30(6):643-8. View abstract
  89. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol. 2009 Sep; 124(3):507-13, 513.e1-7. View abstract
  90. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009 Sep; 124(3 Suppl 2):R7-R12. View abstract
  91. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009 Aug; 124(2):260-9, 269.e1-7. View abstract
  92. Sesame Allergy: Role of Specific IgE and Skin Prick Testing in Predicting Food Challenge Results. J Allergy Clin Immunol. 2009 Feb; 123(2 Suppl 1):S24. View abstract
  93. A girl with severe hand swelling and abdominal cramps. Clin Chem. 2008 Oct; 54(10):1733-6; discussion 1736-7. View abstract
  94. Evaluation of a group intervention for children with food allergy and their parents. Ann Allergy Asthma Immunol. 2008 Aug; 101(2):160-5. View abstract
  95. Hypotension from epinephrine in a food-allergic patient with long QT syndrome. Ann Allergy Asthma Immunol. 2008 Feb; 100(2):174-5. View abstract
  96. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007 Aug; 120(2):416-22. View abstract
  97. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007 Jul; 120(1):150-5. View abstract
  98. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet. 2007 Apr; 39(4):430-1. View abstract
  99. Integrating medical and psychological health care for children with atopic dermatitis. J Pediatr Psychol. 2007 Jun; 32(5):617-25. View abstract
  100. Assessment of adrenal suppression in children with asthma treated with inhaled corticosteroids: use of dehydroepiandrosterone sulfate as a screening test. Ann Allergy Asthma Immunol. 2006 Aug; 97(2):182-6. View abstract
  101. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006 Jul; 26(4):388-95. View abstract
  102. Development of a preliminary questionnaire to assess parental response to children's food allergies. Ann Allergy Asthma Immunol. 2006 Mar; 96(3):472-7. View abstract
  103. Visceral larva migrans associated with earthworm ingestion: clinical evolution in an adolescent patient. Pediatrics. 2006 Feb; 117(2):e336-9. View abstract
  104. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005 Aug; 37(8):829-34. View abstract
  105. Characteristics of mycobacterial infection in patients with immunodeficiency and nuclear factor-kappaB essential modulator mutation, with or without ectodermal dysplasia. J Am Acad Dermatol. 2004 Nov; 51(5):718-22. View abstract
  106. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol. 2004 Apr; 113(4):725-33. View abstract
  107. Clinical features and anaphylaxis in children with cold urticaria. Pediatrics. 2004 Apr; 113(4):e313-7. View abstract
  108. Understanding pediatric inner-city asthma: an explanatory model approach. J Asthma. 2004 Apr; 41(2):167-77. View abstract
  109. A patient with severe black fly (Simuliidae) hypersensitivity referred for evaluation of suspected immunodeficiency. Ann Allergy Asthma Immunol. 2004 Feb; 92(2):276-80. View abstract
  110. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003 Jul; 91(1):49-54. View abstract
  111. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003 Mar 13; 348(11):986-93. View abstract
  112. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest. 2002 Jun; 109(11):1501-9. View abstract
  113. Giant cell myocarditis in a 12-year-old girl with common variable immunodeficiency. Mayo Clin Proc. 2002 Jan; 77(1):92-6. View abstract
  114. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet. 2000 Dec; 67(6):1555-62. View abstract
  115. X-linked hyper IgM syndrome. Clin Rev Allergy Immunol. 2000 Oct; 19(2):205-15. View abstract
  116. Atopic diseases and upper respiratory infections. Curr Opin Pediatr. 2000 Oct; 12(5):511-9. View abstract
  117. Atopic diseases and upper respiratory infections. Curr Opin Pediatr. 1999 Oct; 11(5):475-83. View abstract
  118. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol. 1999 May; 103(5 Pt 1):810-5. View abstract
  119. Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Curr Opin Pediatr. 1998 Oct; 10(5):539-47. View abstract
  120. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol. 1998 Jul; 102(1):113-7. View abstract
  121. Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol. 1998 Mar; 80(3):263-8. View abstract
  122. Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Curr Opin Pediatr. 1997 Oct; 9(5):537-47. View abstract
  123. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA. 1996 Nov 20; 276(19):1563-7. View abstract
  124. Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Curr Opin Pediatr. 1996 Oct; 8(5):531-40. View abstract
  125. Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics. 1996 Aug; 98(2 Pt 1):211-5. View abstract
  126. Intravenous immunoglobulin and hepatitis C virus: the Boston episode. Clin Ther. 1996; 18 Suppl B:108-9. View abstract
  127. Interleukin-4 receptor expression by human B cells: functional analysis with a human interleukin-4 toxin, DAB389IL-4. J Allergy Clin Immunol. 1995 Apr; 95(4):893-900. View abstract
  128. Quality of care for preschool children with asthma: the role of social factors and practice setting. Pediatrics. 1995 Mar; 95(3):389-94. View abstract
  129. Treatment of steroid-dependent asthma with recombinant interferon-gamma. Clin Exp Allergy. 1993 Sep; 23(9):785-90. View abstract
  130. Therapy for patients with recurrent infections and low serum IgG3 levels. J Allergy Clin Immunol. 1993 Aug; 92(2):353-5. View abstract
  131. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol. 1993 Feb; 28(2 Pt 1):189-97. View abstract
  132. Lymphokine profile in bone marrow transplant recipients. Blood. 1991 Dec 01; 78(11):3076-80. View abstract
  133. Induction of germ-line and mature C epsilon transcripts in human B cells stimulated with rIL-4 and EBV. J Immunol. 1990 Nov 15; 145(10):3468-73. View abstract
  134. Regulation of immunoglobulin (Ig)E synthesis in the hyper-IgE syndrome. J Clin Invest. 1990 May; 85(5):1666-71. View abstract
  135. Bone marrow transplantation (BMT) for the syndrome of pigmentary dilution and lymphohistiocytosis (Griscelli's syndrome). J Clin Immunol. 1990 May; 10(3):146-53. View abstract
  136. Response to a Haemophilus influenzae type b diphtheria CRM197 conjugate vaccine in children with a defect of antibody production to Haemophilus influenzae type b polysaccharide. J Allergy Clin Immunol. 1990 May; 85(5):948-53. View abstract